{"id":3566,"date":"2026-10-06T08:13:06","date_gmt":"2026-10-06T02:43:06","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-06\/"},"modified":"2026-10-06T17:16:21","modified_gmt":"2026-10-06T11:46:21","slug":"zyduslife-share-price-today-2026-10-06","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-06\/","title":{"rendered":"Why Zydus Life Shares Are Rising 1.80% Today | 6 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ZYDUSLIFE<\/strong> \u00b7 6 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,159.50<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+1.80%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,164.80 \/ \u20b91,145.20<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,139.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>15.65 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>6 October 2026 \u00b7 03:15 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Zydus Lifesciences Ltd shares moved higher today, trading up 1.80% at \u20b91,159.50. The stock opened at \u20b91,153.00 and oscillated within a day&#x27;s range of \u20b91,145.20 to \u20b91,164.80.<\/li>\n<li>Zydus Lifesciences announced a partnership with MSN Laboratories to launch Riociguat Tablets across all five strengths as the first generic equivalent of Adempas in the United States. The product is indicated for treating pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer&#x27;s 2025 annual report cited in the filing, global sales of the branded product were approximately EUR 745 million.<\/li>\n<li>Trading volume was 0.99 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Zydus Lifesciences share price rising on 6 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Zydus Lifesciences Ltd shares moved higher today, trading up 1.80% at \u20b91,159.50. The stock opened at \u20b91,153.00 and oscillated within a day&#x27;s range of \u20b91,145.20 to \u20b91,164.80.<\/p>\n<p class=\"wt-copy\">The broader market participated in a positive session, with the Nifty advancing 0.98%. Meanwhile, the relevant sectoral benchmark Nifty Pharma rose 1.66%, indicating that the stock&#x27;s 1.80% gain was supported by broader momentum across pharmaceutical counters. Over the preceding five trading days, the stock had experienced a correction of 4.57%, positioning today&#x27;s move as a partial recovery.<\/p>\n<p class=\"wt-copy\">The price action coincides with recent operational updates from the company, including its recent partnership announcement with MSN Laboratories to launch the first generic version of Adempas in the U.S. market.<\/p>\n<p class=\"wt-copy\">15.65 lakh shares traded by 6 October 2026 \u00b7 03:15 PM IST. This compares with a 20-day average daily volume of 15.82 lakh shares (0.99 times). The five-day average daily volume was 24.23 lakh shares. Separately, the NSE report for 5 October 2026 showed 7.84 lakh shares delivered, representing 49.23% of that day\u2019s traded volume. The same report recorded 43,191 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>technical rebound after recent weakness amid sectoral support<\/strong><\/p>\n<p class=\"wt-copy\">The stock moved up by 1.80% following a recent 5-day correction of 4.57%, finding support alongside a strong 1.66% gain in the Nifty Pharma index. While recent business updates such as the U.S. generic launch provide fundamental context, today&#x27;s price action aligns closely with a broader sectoral recovery and a technical bounce from recent lows.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Partnership to Launch First Generic Adempas in U.S.<\/div>\n<div class=\"wt-card-date\">5 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Zydus Lifesciences announced a partnership with MSN Laboratories to launch Riociguat Tablets across all five strengths as the first generic equivalent of Adempas in the United States. The product is indicated for treating pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer&#x27;s 2025 annual report cited in the filing, global sales of the branded product were approximately EUR 745 million.<\/p>\n<p class=\"wt-copy\">First-to-market generic launches in regulated specialty categories expand the company&#x27;s complex generics footprint and revenue potential in the U.S. market.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">USFDA Inspection at Ahmedabad SEZ II Plant<\/div>\n<div class=\"wt-card-date\">28 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The USFDA concluded a cGMP inspection at the company&#x27;s manufacturing plant located at SEZ II in Ahmedabad between September 21 and September 28, 2026. The inspection concluded with a single observation and contained no data integrity related observations. The company stated it will work closely with the regulator to address the observation expeditiously.<\/p>\n<p class=\"wt-copy\">Regulatory compliance and clearance status for key manufacturing facilities are vital for maintaining uninterrupted export execution and approvals.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_28092026180155_PressRelease28092026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">USFDA Audit at New Jersey Office<\/div>\n<div class=\"wt-card-date\">26 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced that an onsite USFDA inspection of pharmacovigilance and post-marketing surveillance systems at its U.S. office in New Jersey concluded with nil observations. The inspection was conducted from September 22 to September 25, 2026. This adds to the regulatory milestones for the company&#x27;s operational compliance framework.<\/p>\n<p class=\"wt-copy\">A clean inspection report reinforces the company&#x27;s adherence to stringent post-marketing surveillance standards in international markets.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_26092026122222_PressRelease26092026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 05, 2026, titled &quot;Zydus, MSN partner to Launch First Generic of Adempas\u00ae (Riociguat Tablets) in the U.S.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_05102026204016_PressRelease05102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated August 31, 2026, titled &quot;Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_31082026104241_PressRelease31082026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">75.01%<\/div>\n<div class=\"wt-note\">75.01% on 18 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">6.88%<\/div>\n<div class=\"wt-note\">6.89% on 18 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">18.15%<\/div>\n<div class=\"wt-note\">18.08% on 18 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1690961_11072026025816_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Jasodaben Babubhai Patel<\/strong><span class=\"wt-note\">Promoter Group<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>1,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>12 November 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 5.12% on 30 June 2026. This compares with 4.92% on 18 June 2026, a change of +0.20 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 38 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Parag Parikh Flexi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">2.02 crore shares \u00b7 2.02%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Kotak Flexicap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">1.19 crore shares \u00b7 1.19%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1690961_11072026025816_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Macquarie<\/div>\n<div class=\"wt-card-date\">27 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Outperform<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained an Outperform rating, focusing on new business buildout and complex product execution to drive long-term growth.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Citi<\/div>\n<div class=\"wt-card-date\">12 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Sell<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Raised target price following earnings but kept a Sell rating due to valuation considerations relative to expected growth.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">20 May 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Neutral<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a Neutral rating reflecting limited immediate upside potential from prevailing valuation levels.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution and market uptake of the newly launched generic Riociguat tablets in the U.S.<\/li>\n<li>Company response and resolution timeline regarding the single USFDA observation at the Ahmedabad SEZ II plant<\/li>\n<li>Sustained delivery participation and cash volume relative to the 20-day moving average<\/li>\n<li>Performance trends within the Nifty Pharma index to gauge continued sector-wide sentiment<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-01\/\">Why Zydus Lifesciences Shares Fell 2.46% Today: Market Context | 1 October 2026 \u2014 1 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-09-30\/\">Why Zydus Lifesciences Shares Fell 3.21% Today: Sector Weakness | 30 September 2026 \u2014 30 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/zyduslife\/\">More Zydus Lifesciences news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Zydus Lifesciences company news?<\/h3>\n<p class=\"wt-copy\">Zydus Lifesciences announced a partnership with MSN Laboratories to launch Riociguat Tablets across all five strengths as the first generic equivalent of Adempas in the United States. The product is indicated for treating pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer&#x27;s 2025 annual report cited in the filing, global sales of the branded product were approximately EUR 745 million.<\/p>\n<h3>How strong was Zydus Lifesciences\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">15.65 lakh shares traded, 0.99 times the 20-day average daily volume. The price and volume data are dated 6 October 2026 \u00b7 03:15 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Article by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-06\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-06\/\"}, \"headline\": \"Why Zydus Life Shares Are Rising 1.80% Today | 6 October 2026\", \"description\": \"Zydus Lifesciences shares rose 1.80% to \u20b91,159.50 today, supported by sectoral momentum in Nifty Pharma and a technical rebound after recent weakness.\", \"datePublished\": \"2026-10-06T02:43:06Z\", \"dateModified\": \"2026-10-06T17:16:10.615062+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/zyduslife-company-news-2026-10-06.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 05, 2026, titled \\\"Zydus, MSN partner to Launch First Generic of Adempas\u00ae (Riociguat Tablets) in the U.S.\\\".\",\"source\":\"NSE\",\"published\":\"05-Oct-2026 20:41:59\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_05102026204016_PressRelease05102026.pdf\",\"disclosure_text\":\"October 5, 2026 BSE Limited Code: 532321 P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, C\/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Re.: Press Release Dear Sir \/ Madam, Please find enclosed a copy of press release dated October 5, 2026, titled \u201cZydus, MSN partner to Launch First Generic of Adempas\u00ae (Riociguat Tablets) in the U.S.\u201d. The contents of the press release give full details. Please bring the aforesaid news to the notice of the members of the exchange and the investors\u2019 at large. Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above ACTIVE\/209678684.2 Zydus, MSN partner to Launch First Generic of Adempas\u00ae (Riociguat Tablets) in the U.S. First-to-market launch brings a lower-cost riociguat to U.S. patients living with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Ahmedabad, India and Pennington, N.J., 5 October 2026 Zydus Lifesciences Limited (Zydus), in partnership with MSN Laboratories Private Limited (MSN), today announced the launch of Riociguat Tablets, 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg, in the United States. Zydus and MSN are the first companies to launch a generic version of Adempas\u00ae (riociguat) in the U.S. market. The product was developed and is manufactured by MSN. Riociguat Tablets are approved by the United States Food and Drug Administration (USFDA) as a generic equivalent of Adempas\u00ae Tablets in all five strengths. Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class; and for adults with pulmonary arterial hypertension (PAH, WHO Group 1), to improve exercise capacity, improve WHO functional class and to delay clinical worsening. Commenting on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, \\\"Being first to market with generic riociguat is a milestone for our U.S. business and for patients with pulmonary hypertension. It reflects the strength of our complex-generics pipeline, our ability to execute day-one launches in specialty categories, and the strength of our partnerships that complement our commercial reach in the United States. We are pleased to enable access to the drug across all five strengths, allowing physicians and pharmacies to transition patients with confidence.\\\" Dr. MSN Reddy, Founder & CMD, MSN Laboratories, said , \\\"Riociguat is a technically demanding molecule, and bringing the first generic to the U.S. demonstrates the depth of MSN's integrated API and formulation R&D and the scale of our manufacturing. Together with Zydus' established U.S. commercial platform, we are confident of delivering consistent, high-quality supply of this important therapy.\\\" ACTIVE\/209678684.2 PAH and CTEPH are rare, progressive and life-threatening conditions in which patients typically remain on therapy for life. So far, riociguat was available in the United States only as the branded product. Sales of riociguat are not reported by IQVIA. According to Bayer's Annual Report 2025, the global sales of Adempas \u00ae were approximately EUR 745 million (approximately USD 850 million) in 2025 (source: https:\/\/www.bayer.com\/sites\/default\/files\/2026-03\/bayer-annual- report-2025.pdf). About Zydus Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com About MSN Laboratories MSN Laboratories Group is a research-driven, fully integrated pharmaceutical company established in 2003, with a mission to make high-quality medicines accessible and affordable worldwide. The group operates 25 manufacturing facilities across India and the USA, supported by a unified R&D ecosystem spanning both API and finished dosage development. With over 1,000 patents filed globally, 200+ ANDA submissions and a leading position in US DMF filings, MSN has built a strong global presence. With a portfolio of 550+ APIs and 400+ finished dosage forms across 35+ therapeutic areas, MSN serves over 50 million patients in more than 100 countries. For more details visit www.msnlabs.com. Adempas\u00ae is a registered trademark of Bayer. All other trademarks are the property of their respective owners. ***\"},{\"summary\":\"a press release dated August 31, 2026, titled \\\"Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH\\\".\",\"category\":\"Press Release\",\"date\":\"31-Aug-2026 10:43:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_31082026104241_PressRelease31082026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"a press release dated October 05, 2026, titled \\\"Zydus, MSN partner to Launch First Generic of Adempas\u00ae (Riociguat Tablets) in the U.S.\\\".\",\"category\":\"Press Release\",\"date\":\"05-Oct-2026 20:41:59\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_05102026204016_PressRelease05102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated August 21, 2026, titled \\\"Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity\\\".\",\"category\":\"Press Release\",\"date\":\"21-Aug-2026 13:52:32\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_21082026135055_PressRelease21082026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"Change in Director(s) of the company.\",\"category\":\"Change in Director(s)\",\"date\":\"11-Aug-2026 20:08:15\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_11082026200546_ChangeinDirectors.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":3},{\"summary\":\"Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4}],\"recent_news\":[{\"summary\":\"a press release dated August 31, 2026, titled \\\"Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH\\\".\",\"category\":\"Press Release\",\"date\":\"31-Aug-2026 10:43:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_31082026104241_PressRelease31082026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Macquarie Hikes Zydus Lifesciences' Target Ahead Of Q1 Results; Bets On New Business Buildout To Drive Growth.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated October 05, 2026, titled \\\"Zydus, MSN partner to Launch First Generic of Adempas\u00ae (Riociguat Tablets) in the U.S.\\\".\",\"category\":\"Press Release\",\"date\":\"05-Oct-2026 20:41:59\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_05102026204016_PressRelease05102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"Jasodaben Babubhai Patel\",\"category\":\"Promoter Group\",\"type\":\"Buy\",\"quantity\":\"1000\",\"post_holding\":\"42577\",\"date\":\"12-Nov-2025\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":75.01,\"public_pct\":24.99,\"fii_pct\":6.88,\"dii_pct\":11.27,\"mf_pct\":5.12,\"institutional_pct\":18.15,\"noninst_pct\":6.83,\"mf_scheme_count\":38,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Parag Parikh Flexi Cap Fund\",\"shares\":20150442,\"pct\":2.02},{\"name\":\"Kotak Flexicap Fund\",\"shares\":11911788,\"pct\":1.19}],\"period\":\"30-JUN-2026\",\"submission_date\":\"11-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1690961_11072026025816_WEB.xml\",\"previous_period\":\"18-JUN-2026\",\"previous_promoter_pct\":75.01,\"previous_fii_pct\":6.89,\"previous_dii_pct\":11.19,\"previous_mf_pct\":4.92,\"previous_institutional_pct\":18.08,\"previous_mf_scheme_count\":37,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Macquarie\",\"rating\":\"Outperform\",\"target\":null,\"view_summary\":\"Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating.\",\"headline\":\"Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why\",\"published\":\"2026-08-27T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Citi\",\"rating\":\"Sell\",\"target\":null,\"view_summary\":\"Citi, Investec Raise Zydus Life Targets But Keep 'Sell'; Is The Stock Still Too Expensive?\",\"headline\":\"Citi, Investec Raise Zydus Life Targets But Keep 'Sell'; Is The Stock Still Too Expensive?\",\"published\":\"2026-08-12T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Neutral\",\"target\":null,\"view_summary\":\"Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside \u2014 Check Revised Target Price\",\"headline\":\"Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside \u2014 Check Revised Target Price\",\"published\":\"2026-05-20T07:00:00+00:00\",\"source\":\"NDTV Profit\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences shares rose 1.80% to \u20b91,159.50 today, supported by sectoral momentum in Nifty Pharma and a technical rebound after recent weakness.<\/p>\n","protected":false},"author":1,"featured_media":3565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Why Zydus Life Shares Are Rising 1.80% Today | 6 October 2026","_witty_meta_description":"Zydus Lifesciences shares rose 1.80% to \u20b91,159.50 today, supported by sectoral momentum in Nifty Pharma and a technical rebound after recent weakness.","_witty_primary_phrase":"why Zydus Life share price is rising today","_witty_reason_label":"technical rebound after recent weakness amid sectoral support","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[122],"class_list":["post-3566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-zyduslife"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/3566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=3566"}],"version-history":[{"count":8,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/3566\/revisions"}],"predecessor-version":[{"id":4310,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/3566\/revisions\/4310"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/3565"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=3566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=3566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=3566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}